Abstract
According to the World Health Organization (WHO) and the Centers for Diseases Control and Prevention (CDC), currently an estimated 3 – 6 % of people suffer from post-COVID condition or syndrome (PCS). A subset meets diagnostic criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Several studies have reported persistence of SARS-CoV-2 proteins or RNA in serum or tissues of both recovered individuals and PCS patients.
In this exploratory study, we investigated whether serum spike protein is associated with PCS and whether it correlates with symptom severity and laboratory biomarkers. We analyzed serum spike protein levels in 121 PCS patients following mild-to-moderate COVID-19, 72 of whom met diagnostic criteria for ME/CFS (post-COVID ME/CFS, pcMECFS). Pre-pandemic seronegative healthy controls (ppHC, n = 32) and post-COVID recovered healthy controls (pcHC, n = 37) after SARS-CoV-2 infection were also included in the study.
We found persistent serum SARS-CoV-2 spike protein in a subset of pcHC (11 %), PCS non-ME/CFS patients (2 %), and pcMECFS patients (14 %). There was no significant association with disease severity, symptoms, or laboratory markers. The spike protein concentration was independent of the time since last spike exposure (infection or vaccination). In five spike-positive out of a total of 22 patients who underwent immunoglobulin depletion via immunoadsorption (IA), spike protein was reduced or completely removed after treatment, indicating binding to immunoglobulins.
In summary, our study identified serum spike protein in a subset of patients after SARS-CoV-2 infection without evidence for a role in the pathogenesis of PCS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the ME/CFS Research foundation and the Lost Voices foundation. AF received a scholarship from the Fridericus foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of Charite - Universitaetsmedizin Berlin gave ethical approval for this work in accordance with the 1964 Declaration of Helsinki and its later amendments (EA2/066/20 and EA2/067/20).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data associated with this study are present in the paper. Correspondence and requests should be addressed to AF.
